Veeva Systems reported faster GAAP earnings growth than revenue during its fiscal second quarter of 2027 as adoption of Vault CRM expanded, its agentic AI products moved further into customer deployments and management raised its full-year outlook.
Total revenue increased 18% year-over-year to $928 million.
Subscription revenue increased 16% to $766.8 million, continuing to represent the large majority of Veeva’s overall business and providing the company with a sizable recurring revenue base across its life sciences software platform.
Profitability increased significantly faster than revenue on a GAAP basis.
GAAP operating income jumped 40% to $275 million from $195.9 million in the prior-year period.
That performance indicates substantial operating leverage as Veeva generated considerably more operating profit from its growing revenue base.
Non-GAAP operating income increased 18% to $415.9 million.
GAAP net income increased 37% to $273.4 million from $200.3 million a year earlier, while diluted GAAP earnings per share increased to $1.66 from $1.19.
On a non-GAAP basis, net income increased 16% to $387.4 million.
Non-GAAP diluted EPS rose to $2.35 from $1.99.
The quarter therefore combined double-digit revenue growth with significantly faster GAAP earnings expansion as Veeva continued scaling its cloud software platform across the global life sciences industry.
Veeva provides software used by pharmaceutical, biotechnology and other life sciences organizations across commercial, clinical, regulatory, quality and safety workflows.
Its products are designed around the highly specialized requirements of the industry, where companies must manage large amounts of regulated data while coordinating complex development and commercialization processes.
That industry focus has allowed Veeva to build a large subscription business around applications that often become embedded in customers’ critical operating workflows.
One of the most important areas of expansion is Vault CRM.
More than 180 customers are now live on Vault CRM, including five of the world’s top 20 biopharmaceutical companies.
Veeva also disclosed that, following additional commitments received during August, 12 of the top 20 biopharma companies globally had committed to Vault CRM.
That level of adoption among the industry’s largest companies represents an important validation of Veeva’s strategy as customers transition onto the platform.
Customer commitments are particularly significant because large global biopharmaceutical companies can have extensive commercial organizations and complex technology environments.
Migrating CRM systems across thousands of employees can therefore involve significant implementation, data migration and change-management work.
Securing commitments from 12 of the top 20 companies gives Veeva a substantial pipeline of future deployments as those organizations move through implementation.
The company is also beginning to connect its artificial intelligence strategy more directly with Vault CRM.
One top-20 biopharmaceutical customer deployed Vault CRM together with Veeva’s Agentic Call Report across its entire U.S. field team.
The deployment provides an early example of how Veeva plans to incorporate agentic AI into the everyday workflows of pharmaceutical sales and commercial organizations.
Call reporting has historically required field representatives to document interactions with healthcare professionals after meetings.
Automating or assisting parts of that process with AI could reduce administrative work and allow representatives to spend more time on customer-facing activities.
Veeva’s broader AI strategy is focused on applying agents to workflows where the company already controls much of the underlying software and data environment.
That positioning could be important because enterprise AI applications often become more valuable when they are integrated directly into the systems employees already use rather than functioning as standalone tools.
Vault CRM provides one environment in which Veeva can introduce those capabilities.
The company’s emerging Veeva Falcon platform extends the agentic strategy beyond commercial operations.
Falcon is being developed as an agentic labor platform for clinical, regulatory and safety workflows.
The product now has five early adopters and remains on track for initial customer go-lives this year.
Clinical, regulatory and safety functions involve large amounts of documentation, data review and process coordination throughout the lifecycle of a medicine.
Veeva is seeking to use AI agents to automate portions of those workflows while operating within the controlled software environments required by life sciences customers.
The concept of agentic labor represents a broader evolution from AI systems that simply generate or summarize information toward software agents capable of completing portions of business processes.
In regulated industries such as pharmaceuticals, successful deployment will require not only technical capabilities but also appropriate controls, auditability and integration with existing systems.
Veeva’s long-standing relationships with life sciences companies and its existing workflow applications could provide an advantage as customers evaluate where AI agents can be deployed safely and effectively.
The five early adopters of Falcon give Veeva an opportunity to test those capabilities in real production environments before expanding availability more broadly.
Initial go-lives could also provide the company with evidence about which workflows generate the greatest productivity gains and where customers are most willing to adopt autonomous or semi-autonomous agents.
The AI strategy could eventually create both new revenue opportunities and additional value within Veeva’s existing subscription base.
If customers use agentic products alongside Vault CRM and other applications, Veeva could deepen its role within customer organizations while increasing the number of products deployed within each account.
That could support higher customer spending and create additional barriers to switching platforms.
The rapid adoption of Vault CRM among major pharmaceutical companies provides a foundation for that strategy.
With more than 180 customers live and 12 of the top 20 global biopharmaceutical companies now committed, Veeva has an expanding installed base into which AI functionality can potentially be introduced.
The quarter’s financial performance suggests that the company is funding these new initiatives while continuing to improve profitability.
GAAP operating income increased 40%, substantially outpacing the 18% increase in total revenue.
GAAP net income also grew at more than twice the rate of revenue, rising 37%.
That operating leverage gives Veeva greater flexibility to continue investing in Vault CRM, Falcon and other products without sacrificing overall earnings growth.
Subscription revenue of $766.8 million remains particularly important because recurring software revenue provides visibility into future results.
As additional Vault CRM commitments convert into live deployments, subscription revenue could receive another source of growth from large enterprise customers.
The company’s broader portfolio also gives it exposure to multiple areas of life sciences spending rather than relying solely on CRM.
Veeva’s software supports activities extending from drug development and regulatory work to commercial execution after products reach the market.
The Falcon initiative is intended to bring AI into some of those development and compliance functions, potentially expanding Veeva’s opportunity across the lifecycle of a medicine.
Management’s confidence in the business led the company to raise its full-year outlook.
Veeva now expects fiscal 2027 revenue of approximately $3.682 billion to $3.687 billion.
At the midpoint, that represents approximately $3.685 billion of annual revenue.
The company also expects approximately $1.64 billion of non-GAAP operating income.
Non-GAAP diluted EPS is projected at approximately $9.21.
The higher outlook reflects continued demand across the platform and increasing visibility into customer deployments.
Vault CRM adoption will remain one of the most closely watched indicators during the remainder of the year.
The transition of large pharmaceutical customers onto Vault CRM can create significant long-term subscription relationships, but implementations can occur over extended periods depending on customer size and complexity.
Veeva’s August commitments from additional top-20 biopharmaceutical companies expand the pipeline of future conversions.
The company’s ability to deploy AI alongside those migrations could make the platform increasingly differentiated.
The full U.S. field-team rollout of Agentic Call Report at one top-20 company demonstrates that at least some large customers are moving beyond small AI experiments and into broader operational deployments.
If similar projects expand across other customers, agentic products could become a more meaningful contributor to Veeva’s growth strategy.
Falcon provides another potential avenue.
Its focus on clinical, regulatory and safety workflows gives Veeva access to areas where pharmaceutical companies spend significant amounts of employee time managing documentation, compliance and operational processes.
Automating portions of those activities could create measurable productivity improvements if the technology performs reliably within regulated environments.
For Veeva, the opportunity is to combine its existing industry-specific applications with AI agents that operate directly inside those workflows.
That approach could make AI functionality a natural extension of products customers already use rather than a separate technology layer.
Overall, Veeva’s fiscal second quarter demonstrated strength across revenue, profitability, customer adoption and product development.
Revenue increased 18% to $928 million, GAAP operating income rose 40% to $275 million and GAAP net income increased 37% to $273.4 million.
Meanwhile, Vault CRM continued gaining traction among the largest pharmaceutical companies, Agentic Call Report reached a major U.S. deployment and Falcon advanced toward its first go-lives.
With 12 of the top 20 global biopharmaceutical companies now committed to Vault CRM and management raising its fiscal 2027 outlook, Veeva enters the second half of the year with a larger recurring-revenue base and growing evidence that its agentic AI strategy is beginning to move from product development into real customer operations.
KEY QUOTE:
“AI is opening up the next big chapter for Veeva and life sciences.”
Peter Gassner, Chief Executive Officer of Veeva Systems
